Replies to post #156515 on NorthWest Biotherapeutics Inc (NWBO)

[marzan]

It works in liquid cancer now in mice and they tried in a colon cancer and it didn't work as of now, imo. They need a infiltrated T-cell protein already inside a solid tumor for this technique to work, imo. DCVax is for all solid cancers and so far Direct is the King in the field. Everyone is trying to duplicate it but we got the patent. Everyone knows immune system dendritic cells are the master killers of solid cancer antigens. And to employ the dendritic cells, looks like they all have to come to NWBO to avoid patent infringement and resultant treble damages if found guilty. We are doing great and we will rule the cancer field, no doubt about it. Go NWBO! Go Linda!!

[pgsd]

Depends IMO (with this and other competition) on Linda's period of "judgement" in ending P3 and then initiating P2 trials with Direct.

[Smokey21]

DCVAX Direct did the same thing in mouse models. Clearly, we are further along, but this and other competition will be on their heals if they don't get Direct phase II moving soon.

[jondoeuk]

Another TLR9 agonist could. In the next few months a PhIII testing intratumoral IMO-2125 (produced by $IDRA) in PD-1 R/R patients will open. They hope to recruit approximately 300 patients at ~70 centers globally.

Two other trials are ongoing in patients with a range of solid tumours (NCT03052205) and metastatic melanoma in combo with either Ipilimumab or Pembrolizumab (NCT02644967).

In the former trial all subjects dosed (N=11) completed the 21 day DLT
period. No DLTs or safety concerns have occurred. Cohort 1 (8 mg) diseases under study included pancreatic cancer (6), ocular melanoma (1), colorectal cancer (1), metastatic chondrosarcoma (1), metastatic breast cancer (1), metastatic esophageal cancer (1). Eight subjects had injections into their liver lesions and now Cohort 2 (16 mg) is enrolling. Three subjects in cohort 1 (8 mg) continue IMO-2125 monotherapy. Initial investigator assessments indicate stable disease in 2 patients (pancreatic, colorectal), and another 1 has irSD (pancreatic).